

W.J. "BILLY" TAUZIN, LOUISIANA  
RALPH M. HALL, TEXAS  
MICHAEL BILIRAKIS, FLORIDA  
FRED UPTON, MICHIGAN  
CLIFF STEARNS, FLORIDA  
PAUL E. GILLMOR, OHIO  
JAMES C. GREENWOOD, PENNSYLVANIA  
CHRISTOPHER COX, CALIFORNIA  
NATHAN DEAL, GEORGIA  
RICHARD BURR, NORTH CAROLINA  
ED WHITFIELD, KENTUCKY  
CHARLIE NORWOOD, GEORGIA  
BARBARA CUBIN, WYOMING  
JOHN SHIMKUS, ILLINOIS  
HEATHER WILSON, NEW MEXICO  
JOHN B. SHADEGG, ARIZONA  
CHARLES W. "CHIP" PICKERING, MISSISSIPPI  
VITO FOSSELLA, NEW YORK  
STEVE BUYER, INDIANA  
GEORGE RADANOVICH, CALIFORNIA  
CHARLES F. BASS, NEW HAMPSHIRE  
JOSEPH R. PITTS, PENNSYLVANIA  
MARY BONO, CALIFORNIA  
GREG WALDEN, OREGON  
LEE TERRY, NEBRASKA  
MIKE FERGUSON, NEW JERSEY  
MIKE ROGERS, MICHIGAN  
DARRELL E. ISSA, CALIFORNIA  
C.L. "BUTCH" OTTER, IDAHO  
JOHN SULLIVAN, OKLAHOMA

BUD ALBRIGHT, STAFF DIRECTOR

ONE HUNDRED EIGHTH CONGRESS

U.S. House of Representatives  
Committee on Energy and Commerce  
Washington, DC 20515-6115

JOE BARTON, TEXAS  
CHAIRMAN

December 3, 2004

JOHN D. DINGELL, MICHIGAN  
HENRY A. WAXMAN, CALIFORNIA  
EDWARD J. MARKEY, MASSACHUSETTS  
RICK BOUCHER, VIRGINIA  
EDOLPHUS TOWNS, NEW YORK  
FRANK PALLONE, Jr., NEW JERSEY  
SHERROD BROWN, OHIO  
BART GORDON, TENNESSEE  
PETER DEUTSCH, FLORIDA  
BOBBY L. RUSH, ILLINOIS  
ANNA G. ESHOO, CALIFORNIA  
BART STUPAK, MICHIGAN  
ELIOT L. ENGEL, NEW YORK  
ALBERT R. WYNN, MARYLAND  
GENE GREEN, TEXAS  
KAREN MCCARTHY, MISSOURI  
TED STRICKLAND, OHIO  
DIANA DeGETTE, COLORADO  
LOIS CAPPS, CALIFORNIA  
MICHAEL F. DOYLE, PENNSYLVANIA  
CHRISTOPHER JOHN, LOUISIANA  
TOM ALLEN, MAINE  
JIM DAVIS, FLORIDA  
JAN SCHAKOWSKY, ILLINOIS  
HILDA L. SOLIS, CALIFORNIA  
CHARLES A. GONZALEZ, TEXAS

Kathleen Coelingh  
Senior Director for Regulatory and  
Scientific Affairs  
MedImmune, Inc.  
One MedImmune Way  
Gaithersburg, MD 20878


Dear Dr. Coelingh:

On November 18, 2004, you testified before the Subcommittee on Health and Subcommittee on Oversight and Investigations in a joint hearing entitled "Flu Vaccine: Protecting High-Risk Individuals and Strengthening the Market." I now request your response to several additional questions (attached).

Because I wish to include the questions and responses in the printed record of this hearing, please respond no later than Friday, December 17, 2004. Please fax and e-mail the responses. The faxed response should be directed to Eugenia Edwards, Committee on Energy and Commerce majority staff, at (202) 226-2447, and Voncille Hines, Committee on Energy and Commerce minority staff, at (202) 225-5288. The e-mail copy of the response should be in MS Word format and directed to Eugenia Edwards ([Eugenia.Edwards@mail.house.gov](mailto:Eugenia.Edwards@mail.house.gov)) and Voncille Hines ([Voncille.Hines@mail.house.gov](mailto:Voncille.Hines@mail.house.gov)). Due to the uncertainties of postal deliveries on Capitol Hill, your response should not be sent through the postal service.

If you have any questions, please contact John Ford, Minority Counsel with the Committee on Energy and Commerce, at (202) 226-3400.

Sincerely,



JOHN D. DINGELL  
RANKING MEMBER

Attachment

Dr. Kathleen Coelingh  
Page 2

cc: The Honorable Joe Barton, Chairman  
Committee on Energy and Commerce

The Honorable Michael Bilirakis, Chairman  
Subcommittee on Health

The Honorable Sherrod Brown, Ranking Member  
Subcommittee on Health

The Honorable Greg Walden, Vice Chairman  
Subcommittee on Oversight and Investigations

The Honorable Peter Deutch, Ranking Member  
Subcommittee on Oversight and Investigations

**Questions for Dr. Kathleen Coelingh**  
**Senior Director for Regulatory and Scientific Affairs**  
**MedImmune, Inc.**  
**from the Honorable John D. Dingell**  
**Committee on Energy and Commerce**  
**regarding the November 18, 2004, Subcommittee on Health and**  
**Subcommittee on Oversight and Investigations**  
**Hearing entitled "Flu Vaccine: Protecting High-Risk Individuals and**  
**Strengthening the Market"**

1. One suggestion for a government-supported surplus vaccine buy back program is for the government to provide an end-of-season, below market price, buy back of surplus doses of flu vaccine up to some prearranged limit. Do you agree with this suggestion? If so, please provide details on how you think a buy back program should work. If not, what alternative programs do you recommend?
2. It is clear that much of the distribution and reallocation that takes place during a shortage happens from the goodwill of persons who could refuse to comply with requests to give up supplies that they own. Please comment on whether you believe states have adequate authority to require redistribution in a shortage. The state of Michigan, for example, is operating under a public health order, but many states either do not have this authority or are not exercising it. What criteria should apply to such authority? For example, should this only be triggered upon declaration of a public health emergency? What limits in scope and duration should apply to such authority? Finally, what penalties should apply to violation of an order? Please also answer this question from the perspective of federal authority. Does the Federal Government need more authority to deal with severe vaccine shortages? If so, or if not, please explain.
3. Some believe that the current GMPs (FDA's good manufacturing practice standards for how to run a vaccine production facility) may not be adequate to protect public health. Others believe that one reason we have so few participants in the flu vaccine business is the GMPs are unduly burdensome and that less burdensome alternatives could be adopted. Please indicate which view you hold and explain with some specific examples how the GMPs should be altered.
4. Are there elements of FDA's pre-market review of vaccines that you think need to be changed in order to obtain an adequate and reliable supply of safe and effective flu vaccines? Please be specific.
5. Do you believe that inclusion of the flu vaccine in the Vaccine Injury Compensation Program is adequate to alleviate any reasonable liability concerns? If not, please explain what else you think needs to be done.